rna
interfer
rnai
power
method
specif
gene
silenc
may
also
lead
promis
novel
therapeut
strategi
mediat
small
interf
rna
sirna
sequencespecif
trigger
cleavag
subsequ
degrad
target
mrna
one
critic
factor
abil
deliv
intact
sirna
target
cellsorgan
vivo
review
highlight
mechan
rnai
guidelin
design
optim
sirna
give
overview
studi
base
system
local
applic
nake
sirna
use
variou
nonvir
sirna
deliveri
system
one
promis
avenu
complex
sirna
polyethylenimin
pei
effici
stabil
sirna
upon
system
administr
lead
deliveri
intact
sirna
differ
organ
antitumorigen
effect
peisirnamedi
vivo
genetarget
tumorrelev
protein
like
mous
tumor
xenograft
model
describ
rnai
evolutionarili
conserv
sequencespecif
posttranscript
gene
silenc
phenomenon
trigger
journal
biomedicin
biotechnolog
dna
dna
dsrna
dsrna
process
dicer
atp
sirna
adp
p
interferon
respons
nonspecif
gene
silenc
risc
assembl
risc
activ
bind
risc
target
mrna
mrna
degrad
cleavag
target
mrna
express
risc
atp
adp
p
risc
figur
mechan
rna
interfer
rnai
mammalian
system
long
doublestrand
rna
molecul
dsrna
express
dna
vector
left
red
arrow
directli
enter
cell
center
red
arrow
process
dicer
complex
result
format
small
inhibitori
rna
sirna
altern
induc
rnai
small
bp
duplex
directli
deliv
cell
right
red
arrow
sirna
incorpor
nucleasecontain
multiprotein
complex
call
risc
becom
activ
upon
atpdepend
unwind
sirna
duplex
rna
helicas
singlestrand
sirna
guid
risc
complex
complementari
target
mrna
cleav
endonucleolyt
activ
risc
risc
complex
recov
cycl
cleav
mrna
molecul
rapidli
degrad
due
unprotect
rna
end
alter
express
level
certain
gene
play
pivot
role
sever
patholog
condit
exampl
mani
cancer
upregul
certain
growth
factor
growth
factor
receptor
deregul
intracellular
signal
transduct
pathway
repres
key
element
process
malign
transform
progress
normal
cell
toward
tumor
cell
lead
uncontrol
prolifer
decreas
apoptosi
sinc
process
may
result
direct
autocrin
stimul
tumor
cell
well
paracrin
stimul
cell
includ
stimul
tumorangiogenesi
mani
novel
therapeut
strategi
focu
revers
effect
inhibit
protein
downregul
express
likewis
sever
diseas
firmli
link
express
endogen
wildtyp
mutat
gene
taken
togeth
addit
strategi
base
inhibit
target
protein
exampl
low
molecular
weight
inhibitor
inhibitori
antibodi
open
avenu
genetarget
approach
aim
decreas
express
respect
gene
first
method
introduc
specif
inhibit
gene
express
use
antisens
oligonucleotid
late
upon
introduct
cell
antisens
odn
abl
hybrid
target
rna
lead
degrad
rnadna
hybrid
doubl
strand
rnaas
h
inhibit
translat
target
mrna
due
steric
conform
obstacl
protein
translat
andor
inhibit
correct
splice
earli
discoveri
ribozym
catalyt
activ
rna
abl
sequencespecif
cleav
target
mrna
expand
genetarget
strategi
subsequ
method
extens
studi
develop
regard
optim
target
efficaci
antisenseodnribozym
deliveri
strategi
vitro
vivo
recent
anoth
natur
occur
biolog
strategi
gene
silenc
discov
term
rna
interfer
rnai
sinc
rnai
repres
particularli
power
method
specif
gene
silenc
abl
provid
rel
easi
ablat
express
given
target
gene
commonli
use
tool
biolog
biomed
research
includ
rnaimedi
target
vitro
vivo
function
studi
variou
gene
whose
express
known
upregul
well
develop
novel
therapeut
approach
base
gene
target
doublestrand
rna
molecul
describ
first
c
elegan
fire
et
al
introduc
name
rna
interfer
find
also
explain
earlier
observ
petunia
turn
white
rather
purpl
upon
introduct
purpl
gene
form
dsrna
gene
silenc
antisens
oligonucleotid
well
sens
oligonucleotid
c
elegan
subsequ
studi
demonstr
rnai
describ
differ
name
posttranscript
gene
silenc
ptg
cosuppress
quell
present
eukaryot
organ
respons
dsrna
howev
complic
higher
organ
rnai
reli
multistep
intracellular
pathway
roughli
divid
two
phase
initi
phase
effector
phase
initi
phase
doublestrand
rna
molecul
endogen
exogen
origin
present
cell
process
cleavag
activ
ribonucleas
iiityp
protein
short
nucleotid
fragment
term
sirna
effector
sirna
contain
symmetr
nt
overhang
end
well
phosphat
group
effector
phase
incorpor
nucleasecontain
multiprotein
complex
call
risc
rnainduc
silenc
complex
sever
structur
biochem
studi
shed
light
process
doublestrand
rna
format
risc
complex
see
eg
recent
review
unwind
sirna
duplex
rna
helicas
activ
complex
becom
activ
singlestrand
sirna
guid
risc
complex
complementari
target
rna
upon
bind
sirna
hybrid
target
mrna
risc
complex
catalys
endonucleolyt
cleavag
mrna
strand
within
target
site
due
gener
unprotect
rna
end
result
rapid
degrad
mrna
molecul
risc
complex
recov
bind
cleavag
cycl
whole
process
translat
net
reduct
specif
mrna
level
henc
decreas
express
correspond
gene
overview
rnai
pathway
see
figur
mechan
becom
obviou
sirna
molecul
complementari
target
mrna
thu
abl
serv
guid
sequenc
risc
complex
play
pivot
role
process
need
deriv
long
doublestrand
precursor
molecul
rather
omit
initi
phase
deliv
directli
target
cell
figur
upper
right
arrow
sever
studi
led
develop
guidelin
gener
sirna
optim
term
efficaci
specif
includ
initi
definit
prefer
length
bp
combin
low
gc
content
rang
requir
symmetr
nt
overhang
end
later
studi
synthet
sirna
molecul
howev
reveal
higher
target
efficaci
case
even
longer
duplex
nucleotid
act
substrat
dicer
therefor
allow
direct
incorpor
newli
produc
sirna
risc
complex
expect
intramolecular
foldback
structur
result
intern
repeat
palindrom
sequenc
decreas
number
function
sirna
molecul
silenc
capabl
addit
silencingenhanc
criteria
includ
posit
g
posit
sens
strand
absenc
c
g
posit
importantli
u
posit
sens
strand
sinc
nucleotid
repres
site
riscmedi
cleavag
target
mrna
indic
risc
compar
endonucleas
preferenti
cleav
u
rather
nucleotid
furthermor
shown
gener
thermodynam
flexibl
posit
sens
strand
correl
silenc
efficaci
presenc
least
one
au
base
pair
region
improv
sirnamedi
silenc
efficaci
due
decreas
intern
stabil
end
still
differ
sirna
sequenc
may
display
differ
efficaci
suggest
addit
still
unknown
criteria
optim
sirna
select
emphas
influenc
target
mrna
access
fact
sever
studi
also
correl
sirna
efficaci
mrna
secondari
structur
conclus
apart
select
criteria
defin
individu
screen
differ
sirna
highli
effici
specif
duplex
pool
multipl
sirna
effect
approach
increas
sirnamedi
target
efficaci
design
effect
sirna
sever
algorithm
publicli
access
web
site
avail
see
review
reduc
risk
nonspecif
offtarget
effect
sirna
homolog
search
target
sequenc
gene
databas
necessari
alreadi
incorpor
web
site
nevertheless
also
shown
sirna
may
crossreact
target
limit
sequenc
similar
region
partial
sequenc
ident
target
mrna
sirna
exist
fact
case
region
compris
contigu
nucleotid
sequenc
ident
suffici
induc
gene
silenc
predict
offtarget
activ
difficult
far
addit
mechan
may
lead
nonspecif
effect
vivo
reli
interferon
system
induc
doublestrand
rna
molecul
enter
cell
activ
multicompon
signal
complex
effect
particularli
true
long
dsrna
molecul
essenti
prevent
use
induc
rna
interfer
mammalian
system
develop
synthet
sirna
larg
circumv
problem
sinc
seem
small
howev
synthet
sirna
induc
compon
interferon
system
seem
depend
sequenc
well
case
vitro
transcrib
sirna
initi
triphosph
thu
strategi
avoid
far
possibl
unwant
interferon
respons
upon
applic
sirna
vivo
includ
design
sirna
without
known
interferonstimul
sequenc
use
lowest
possibl
sirna
dose
still
achiev
desir
effect
optim
sirna
deliveri
method
base
known
mechan
antisens
technolog
ribozymetarget
rnai
small
oligonucleotid
plasmidbas
express
vector
use
specif
downregul
express
given
gene
interest
patholog
relev
vitro
principl
also
appli
vivo
situat
lead
novel
potenti
relev
therapeut
approach
deliveri
therapeut
nucleic
acid
viral
vector
use
advantag
high
transfect
efficaci
due
inher
abil
virus
transport
genet
materi
cell
hand
howev
viral
system
show
limit
load
capac
regard
genet
materi
rather
difficult
produc
larger
scale
importantli
pose
sever
safeti
risk
due
oncogen
potenti
inflammatori
immunogen
effect
prevent
repeat
administr
light
problem
concern
limit
nonvir
system
emerg
promis
altern
gene
deliveri
main
requir
protect
nucleic
acid
load
well
effici
uptak
target
cell
subsequ
releas
dna
rna
molecul
necessari
transfer
nucleu
sever
strategi
distinguish
mainli
lipofect
polyfect
reli
cation
lipid
polym
respect
see
eg
effici
protect
enzymat
nonenzymat
degrad
particularli
import
rna
molecul
includ
sirna
fact
therapeut
potenti
sirna
treatment
variou
diseas
principl
promis
limit
transfer
vector
may
turn
ratelimit
develop
rnaibas
therapeut
strategi
one
approach
solv
problem
use
dna
express
plasmid
encod
palindrom
hairpin
loop
desir
sequenc
upon
transcript
fold
rna
doublestrand
short
hairpin
rna
shrna
recogn
dicer
cleav
desir
sirna
addit
vitro
method
describ
recent
base
express
shrna
e
coli
deliveri
via
bacteri
invas
differ
dnabas
system
offer
advantag
sirna
express
longer
durat
probabl
higher
level
gene
silenc
still
reli
viral
nonvir
deliveri
dna
molecul
rais
safeti
issu
vivo
henc
direct
deliveri
sirna
molecul
deriv
vitro
transcript
chemic
synthes
offer
advantag
dnabas
strategi
may
prefer
vivo
therapeut
use
last
year
larg
bodi
studi
publish
describ
differ
strategi
system
local
applic
sirna
vivo
tabl
give
overview
probabl
largest
number
paper
focus
use
unmodifi
sirna
tabl
whose
administr
often
perform
iv
hydrodynam
transfect
high
pressur
tail
vein
inject
method
wide
use
case
led
effici
target
gene
inhibit
liver
lesser
extent
lung
spleen
pancrea
kidney
may
suffer
certain
technic
practic
limit
least
therapeut
set
sinc
reli
rapid
iv
inject
compar
larg
volum
mlmouseinject
theori
equival
l
iv
bolu
inject
man
altern
strategi
applic
nake
sirna
includ
variou
deliveri
rout
howev
often
provid
local
administr
reli
administr
least
close
target
tissu
target
organ
thu
restrict
number
target
organ
may
relev
certain
diseas
also
note
sever
studi
describ
use
rather
larg
amount
sirna
upon
intraven
inject
sirna
liver
primari
site
sirna
uptak
altern
approach
applic
sirna
vivo
deliveri
liposomescation
lipid
describ
liposomebas
sirna
formul
wide
varieti
mode
applic
allow
local
system
deliveri
use
tabl
final
sever
strategi
local
system
sirna
administr
explor
includ
chemic
modif
sirna
molecul
electropuls
polyamin
basic
complex
atelocollagen
virosom
certain
protein
prepar
tabl
altern
approach
reli
complex
unmodifi
sirna
molecul
cation
polym
polyethylenimin
pei
polyethylenimin
pei
synthet
polym
avail
branch
linear
form
figur
upper
panel
broad
rang
molecular
weight
da
kd
commerci
pei
prepar
although
label
defin
molecular
weight
consist
pei
molecul
broad
molecular
weight
distribut
pei
possess
high
cation
charg
densiti
due
proton
amino
group
everi
third
posit
sinc
quarternari
amino
group
present
cation
charg
gener
proton
amino
group
henc
depend
ph
environ
eg
ph
see
review
due
abil
condens
compact
dna
complex
form
small
colloid
particl
allow
effici
cellular
uptak
endocytosi
pei
introduc
potent
dna
transfect
reagent
varieti
cell
line
anim
dna
deliveri
review
see
refer
therein
fact
sever
studi
pei
shown
abl
deliv
larg
dna
molecul
mb
yeast
artifici
chromosom
yac
well
plasmid
small
oligonucleotid
mammalian
cell
vitro
vivo
np
ratio
indic
ratio
nitrogen
atom
pei
dna
phosphat
complex
thu
describ
amount
pei
use
complex
format
independ
molecular
weight
influenc
effici
dna
deliveri
posit
net
charg
complex
result
high
np
ratio
inhibit
due
electrostat
repuls
aggreg
improv
solubl
aqueou
solut
well
interact
neg
charg
extracellular
matrix
compon
thu
cellular
uptak
addit
strong
buffer
capac
describ
proton
spong
hypothesi
postul
enhanc
transgen
deliveri
cation
polymerdna
complex
polyplex
contain
h
buffer
polyamin
due
enhanc
endosom
cl
accumul
osmot
swellinglysi
seem
respons
fact
peibas
deliveri
requir
endosom
disrupt
agent
lysosom
escap
tight
condens
dna
molecul
well
buffer
capac
pei
certain
cellular
compart
like
endosom
lysosom
also
protect
dna
degrad
pei
success
use
nonvir
gene
deliveri
vitro
vivo
initi
public
show
increas
transfect
efficaci
use
high
molecular
weight
pei
recent
studi
demonstr
advantag
certain
low
molecular
weight
pei
higher
transfect
efficaci
low
molecular
weight
pei
may
due
effici
uptak
result
peidna
complex
better
intracellular
releas
dna
andor
lower
vitro
cytotox
compar
high
molecular
weight
pei
fact
decreas
molecular
weight
pei
lead
increas
complex
size
may
favour
least
vitro
use
hand
pei
low
molecular
weight
kd
display
littl
transfect
efficaci
even
high
np
ratio
may
attribut
fact
decreas
molecular
weight
pei
shown
translat
increasingli
lower
abil
form
small
complex
therefor
low
molecular
weight
pei
requir
higher
np
ratio
optim
transfect
efficaci
compar
higher
molecular
weight
pei
sinc
higher
np
ratio
lead
increas
compact
reduc
complex
size
reduc
tendenc
complex
aggreg
due
hydrophob
interact
nevertheless
sever
paramet
extens
studi
precis
determin
transfect
efficaci
remain
elucid
see
review
also
mechan
cytotox
effect
pei
complex
poorli
understood
may
reli
format
larg
aggreg
rang
form
cell
surfac
impair
membran
function
final
lead
cell
necrosi
clearli
trend
toward
low
molecular
weight
pei
rather
nontox
deliveri
reagent
vitro
vivo
combin
high
biocompat
reduc
sideeffect
thu
also
allow
employ
larger
peidna
complex
amount
without
signific
cytotox
recent
use
polyethylenimin
extend
toward
complex
deliveri
rna
molecul
especi
small
rna
molecul
like
nt
allrna
ribozym
sirna
figur
chemic
unmodifi
rna
molecul
instabl
prone
rapid
degrad
pei
complex
shown
lead
almost
complet
protect
enzymat
nonenzymat
degrad
fact
peicomplex
sirna
p
label
better
detect
remain
intact
vitro
sever
hour
even
presenc
rnase
fetal
calf
serum
c
noncomplex
sirna
rapidli
degrad
figur
indic
sirna
molecul
effici
condens
thu
fulli
cover
protect
pei
inde
analysi
peisirna
complex
atom
forc
microscopi
show
absenc
free
sirna
sirna
molecul
end
thu
confirm
find
regard
effici
complex
grzelinski
et
al
submit
howev
complex
stabil
seem
suffici
sirna
protect
pei
test
werth
et
al
press
aigner
et
al
unpublish
data
sever
complex
show
target
efficaci
fact
use
certain
polyethylenimin
peisirna
complex
effici
deliv
target
cell
vitro
sirna
releas
display
bioactiv
figur
gener
seen
peidna
complex
see
transfect
efficaci
depend
pei
use
also
indic
sirna
target
effici
mainli
depend
endocytot
uptak
complex
andor
intracellular
decomposit
rather
vitro
complex
stabil
good
result
obtain
commerci
avail
jetpei
vivo
jetpei
supplier
show
poor
sirna
deliveri
efficaci
likewis
novel
low
molecular
weight
pei
base
fraction
commerci
avail
polyethylenimin
demonstr
high
sirna
protect
deliveri
efficaci
vitro
werth
et
al
press
certain
condit
peirna
sirna
ribozym
complex
retain
physic
stabil
biolog
activ
also
lyophil
werth
et
al
press
although
pei
transfect
transient
data
lab
show
peisirna
effect
stabl
least
day
urbanklein
aigner
unpublish
result
final
anoth
studi
explor
use
sirna
nanoplex
compris
pei
pegyl
rgd
peptid
ligand
attach
distal
end
pei
sirna
nanoplex
protect
sirna
serum
degrad
show
vitro
activ
ultim
goal
applic
sirna
vivo
explor
studi
differ
mous
model
ge
et
al
show
peicomplex
sirna
target
conserv
region
influenza
viru
gene
abl
prevent
treat
influenza
viru
infect
mice
upon
iv
inject
pei
promot
deliveri
sirna
lung
either
given
viru
infect
sirna
reduc
influenza
viru
product
lung
biolog
effect
system
applic
peicomplex
sirna
howev
determin
differ
mous
tumor
model
target
differ
protein
shown
previous
tumorrelev
includ
epiderm
growth
factor
receptor
growth
factor
pleiotrophin
ptn
vascular
endotheli
growth
factor
vegf
receptor
vegf
fibroblast
growth
factorbind
protein
fgfbp
vivo
administr
pei
complex
nake
sirna
ip
subcutan
inject
result
detect
intact
sirna
even
hour
inject
figur
b
radiolabel
sirna
molecul
found
sever
organ
includ
subcutan
tumor
muscl
liver
kidney
smaller
extent
lung
brain
import
note
sirna
actual
intern
tissu
indic
fact
blood
neg
sirna
figur
b
overexpress
receptor
observ
wide
varieti
human
cancer
cancer
cell
line
sinc
display
strong
cell
growthstimul
antiapoptot
effect
especi
heterodim
format
member
egfr
famili
overexpress
establish
neg
prognost
factor
link
aggress
malign
behaviour
tumor
eg
consequ
qualifi
attract
target
molecul
antitumor
treatment
strategi
includ
antibodi
low
molecular
weight
inhibitor
genetarget
approach
fact
relev
express
tumor
growth
establish
sever
vitro
target
studi
includ
use
ribozym
sirna
propos
mechan
peimedi
sirna
transfer
due
electrostat
interact
pei
abl
complex
neg
charg
sirna
lead
compact
format
small
colloid
particl
endocytos
proton
spong
effect
exhibit
pei
complex
lead
osmot
swell
ultim
disrupt
endosom
sirna
protect
degrad
due
tight
condens
complex
buffer
capac
pei
upon
releas
peibas
complex
intact
sirna
incorpor
risc
complex
induc
rnai
see
figur
demonstr
reduct
vitro
lead
among
other
inhibit
cell
prolifer
increas
apoptosi
system
treatment
athym
nude
mice
bear
subcutan
ovarian
carcinoma
tumor
xenograft
ip
inject
peicomplex
sirna
led
mark
antitumor
effect
seen
signific
reduct
tumor
growth
figur
peicomplex
nonspecif
sirna
nake
sirna
effect
parallel
detect
intact
sirna
tumor
specif
treatment
group
alreadi
min
administr
least
h
downregul
mrna
protein
level
anoth
receptor
vegf
target
studi
employ
selfassembl
nanoparticl
base
sirna
complex
pei
pegyl
rgd
peptid
ligand
attach
distal
end
peg
pegyl
allow
steric
stabil
reduc
nonspecif
interact
complex
rgd
motif
provid
tumor
select
due
abil
target
integrin
express
activ
endotheli
cell
tumor
vasculatur
upon
iv
administr
mice
bear
subcutan
neuroblastoma
tumor
xenograft
select
tumor
uptak
vegf
downregul
observ
result
decreas
tumor
growth
tumor
angiogenesi
receptor
ligand
vegf
mitogen
angiogen
growth
factor
stimul
tumor
growth
angiogenesi
sever
tumor
includ
prostat
carcinoma
thu
may
repres
attract
target
molecul
rnaibas
genetarget
strategi
also
bear
mind
doubl
antitumor
effect
due
reduct
tumor
cell
prolifer
well
tumor
angiogenesi
subcutan
intraperiton
inject
vegfspecif
sirna
complex
novel
pei
obtain
fraction
commerci
avail
pei
werth
et
al
press
result
reduct
tumor
growth
due
decreas
vegf
express
level
aigner
unpublish
result
true
peisirnamedi
target
fgfbp
dai
aigner
unpublish
result
establish
figur
protect
vivo
deliveri
sirna
upon
pei
complex
vitro
protect
sirna
nucleolyt
degrad
p
endlabel
sirna
complex
upper
panel
complex
lower
panel
pei
subject
treatment
fetal
calf
serum
c
time
point
indic
sampl
analys
agaros
gel
electrophoresi
blot
autoradiographi
band
repres
fulllength
sirna
molecul
indic
pei
complex
lead
effici
protect
sirna
noncomplex
sirna
rapidli
degrad
b
c
vivo
deliveri
intact
sirna
upon
pei
complex
p
label
sirna
complex
complex
pei
inject
ip
mice
bear
subcutan
ovarian
carcinoma
cell
tumor
xenograft
min
b
h
b
total
rna
variou
organ
tissu
homogen
prepar
subject
agaros
gel
electrophoresi
prior
blot
autoradiographi
band
repres
intact
p
label
sirna
molecul
sever
hour
mainli
found
tumor
muscl
well
liver
timedepend
kidney
littl
sirna
amount
detect
lung
trace
brain
previous
ratelimit
tumor
growth
angiogenesi
sever
tumor
see
review
final
peisirnamedi
target
pleiotrophin
ptn
exert
strong
antitumor
effect
ptn
secret
growth
factor
show
mitogen
chemotact
angiogen
transform
activ
markedli
upregul
sever
human
tumor
includ
cancer
breast
testi
prostat
pancrea
lung
well
melanoma
meningioma
neuroblastoma
glioblastoma
vivo
treatment
nude
mice
system
subcutan
ip
applic
peicomplex
ptn
sirna
led
deliveri
intact
sirna
subcutan
tumor
xenograft
signific
inhibit
tumor
growth
likewis
clinic
relev
orthotop
mous
glioblastoma
model
cell
grow
intracrani
inject
peicomplex
ptn
sirna
cn
exert
antitumor
effect
establish
also
complex
relev
orthotop
tumor
model
potenti
peisirnamedi
ptn
gene
target
novel
therapeut
option
gbm
extend
mode
deliveri
peisirna
complex
intrathec
strategi
employ
therapi
glioblastoma
antisens
oligonucleotid
year
discoveri
sirna
catch
ribozym
antisens
oligonucleotid
effici
tool
gene
target
vitro
recent
also
vivo
includ
explor
potenti
therapeut
lead
develop
sirnabas
therapeut
strategi
ultim
success
howev
figur
system
treatment
mice
peicomplex
sirna
lead
reduc
growth
subcutan
tumor
xenograft
due
decreas
express
athym
nude
mice
bear
subcutan
tumor
xenograft
inject
ip
nmole
nake
open
circl
peicomplex
close
circl
sirna
time
per
week
tumor
size
evalu
daili
product
perpendicular
diamet
tumor
mean
standard
error
mean
sem
depict
student
unpair
test
use
comparison
data
set
p
p
differ
tumor
growth
reach
signific
day
indic
antitumor
effect
peicomplex
sirna
strongli
depend
develop
power
feasibl
sirna
deliveri
strategi
need
address
sever
issu
includ
stabilitystabil
sirna
molecul
preserv
efficaci
maintain
genesilenc
activ
effici
deliveri
target
organ
well
suffici
long
sirna
half
life
organ
particularli
target
organ
thu
sirna
deliveri
strategi
must
provid
sirna
protect
transfect
efficaci
absenc
toxic
nonspecif
effect
must
efficaci
also
use
small
amount
sirna
must
applic
variou
treatment
regimen
variou
diseas
even
requir
overcom
biolog
barrier
administr
reach
target
tissu
target
organ
research
done
dnabas
gene
deliveri
ribozymetarget
antisens
technolog
facilit
process
sinc
alreadi
provid
basi
establish
technolog
also
true
complex
sirna
polyethylenimin
may
repres
promis
avenu
sirna
applic
vivo
may
eventu
lead
novel
therapeut
strategi
work
aigner
support
deutsch
forschungsgemeinschaft
ai
deutsch
krebshilf
author
would
like
apolog
author
whose
primari
work
cite
due
length
consider
